Emerging therapies in malignant pleural mesothelioma

Anti-angiogenic therapies for malignant pleural mesothelioma.

INTRODUCTION Malignant pleural mesothelioma (MPM) is a disease with a dismal prognosis. Currently available treatments have modest results. Therefore, new agents and new treatment strategies are eagerly awaited by patients and clinicians. Preclinical and clinical studies have shown that angiogenesis plays a very important role in MPM. Therefore, a great hope has been placed in the use of anti-a...

Malignant Pleural Mesothelioma: Treatment Options and Novel Therapies

Malignant pleural mesothelioma is a rare primary tumor rising from the pleura and is associated with exposure to asbestos fibers. Mesothelioma is a locally aggressive disease that usually presents at an advanced stage and has a median overall survival of 1 year. Treatment options rarely result in cure of disease and range from trimodality treatment, including chemotherapy, radiation, and surger...

Malignant Pleural Mesothelioma and the Role of Non– Operative Therapies

[Malignant pleural mesothelioma].

Overview Mesothelioma is a rare cancer that is estimated to occur in approximately 2500 people in the United States every year.1,2 These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on malignant pleural mesothelioma (MPM), which is the most common type; mesothelioma can also occur in other sites (e.g., peritoneum, pericardium, tunica vaginalis testis). The disease is di...

Malignant pleural mesothelioma.

Malignant pleural mesotheliomas are tumors originating in the serosal lining of the pleural cavities. Although these are relatively rare tumors, an increasing number of cases are anticipated over the next decade. Patients with these tumors, which are almost invariably fatal, usually have an interval of less than two years between the onset of symptoms and death. There is a well established link...